Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo.
OBJECTIVE
We assessed to what degree smokers who fail to quit on the target quit date (TQD) or lapse following TQD eventually achieve success with continued treatment.


METHODS
A secondary analysis of pooled data of successful quitters treated with varenicline (306 of 696), bupropion (199 of 671) and placebo (121 of 685) from two identically-designed clinical trials of varenicline versus bupropion sustained-release and placebo.


METHODS
Multiple research centers in the US.


METHODS
Adult smokers (n==2052) randomized to 12 weeks drug treatment plus 40 weeks follow-up.


METHODS
The primary end-point for the trials was continuous abstinence for weeks 9-12. TQD was day 8. Two patterns of successful quitting were identified. Immediate quitters (IQs) were continuously abstinent for weeks 2-12. Delayed quitters (DQs) smoked during 1 or more weeks for weeks 2-8.


RESULTS
Cumulative continuous abstinence (IQs + DQs) increased for all treatments during weeks 3-8. Overall IQs and DQs for varenicline were (24%; 20%) versus bupropion (18.0%, P=0.007; 11.6%, P<0.001) or placebo (10.2%, P<0.001; 7.5%, P<0.001). However, DQs as a proportion of successful quitters was similar for all treatments (varenicline 45%; bupropion 39%; placebo 42%) and accounted for approximately one-third of those remaining continuously abstinent for weeks 9-52. No gender differences were observed by quit pattern. Post-treatment relapse was similar across groups.


CONCLUSIONS
Our data support continuing cessation treatments without interruption for smokers motivated to remain in the quitting process despite lack of success early in the treatment.
Gonzales
David
D
OHSU Smoking Cessation Center, Department of Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239-3098, USA. gonzales@ohsu.edu
Jorenby
Douglas E
DE
Brandon
Thomas H
TH
Arteaga
Carmen
C
Lee
Theodore C
TC
D000293:Adolescent; D000328:Adult; D000368:Aged; D001552:Benzazepines / Q000627:therapeutic use*; D001944:Breath Tests; D016642:Bupropion / Q000627:therapeutic use*; D002248:Carbon Monoxide / Q000032:analysis; D003692:Delayed-Action Preparations; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use*; D004348:Drug Labeling; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009042:Motivation; D018722:Nicotinic Agonists / Q000627:therapeutic use*; D010919:Placebos; D011810:Quinoxalines / Q000627:therapeutic use*; D055502:Secondary Prevention; D012907:Smoking / Q000188:drug therapy*; D016540:Smoking Cessation / Q000379:methods / Q000523:psychology / Q000706:statistics & numerical data*; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy; D013997:Time Factors; D016896:Treatment Outcome; D000068580:Varenicline; D055815:Young Adult
D001552:Benzazepines; D003692:Delayed-Action Preparations; D018765:Dopamine Uptake Inhibitors; D018722:Nicotinic Agonists; D010919:Placebos; D011810:Quinoxalines; D016642:Bupropion; D002248:Carbon Monoxide; D000068580:Varenicline
Addiction. 2005 Mar;100(3):299-303
15733243
N Engl J Med. 1997 Oct 23;337(17):1195-202
9337378
Int J Behav Med. 2006;13(1):79-88
16503844
Clin Ther. 2008 Oct;30(10):1852-8
19014840
Drug Alcohol Depend. 2010 Jun 1;109(1-3):120-5
20071105
Addict Behav. 2001 May-Jun;26(3):311-27
11436924
Chest. 2001 May;119(5):1357-64
11348939
Arch Intern Med. 1997 Feb 10;157(3):335-40
9040302
J Behav Med. 1989 Apr;12(2):159-82
2668531
JAMA. 2006 Jul 5;296(1):56-63
16820547
JAMA. 2006 Jul 5;296(1):47-55
16820546
Nicotine Tob Res. 2003 Feb;5(1):13-25
12745503
J Consult Clin Psychol. 2006 Apr;74(2):276-85
16649872
Addiction. 2009 Sep;104(9):1597-602
19686530
N Engl J Med. 1999 Mar 4;340(9):685-91
10053177
JAMA. 2006 Jul 5;296(1):64-71
16820548
Addiction. 2001 Jun;96(6):891-902
11399220
MMWR Morb Mortal Wkly Rep. 1999 Nov 5;48(43):993-6
10577493
JAMA. 1994 Feb 23;271(8):589-94
8301790
Addiction. 2004 Mar;99(3):378-85
14982551
Clin Pharmacol Ther. 2001 Jun;69(6):438-44
11406741
Respir Care. 2000 Oct;45(10):1196-9
11203101
Ann Intern Med. 2001 Sep 18;135(6):423-33
11560455
Am J Prev Med. 2008 Mar;34(3):212-5
18312809
Nicotine Tob Res. 2009 Sep;11(9):1083-92
19561132
Am J Health Behav. 2008 Nov-Dec;32(6):664-75
18442345
Health Psychol. 2000 Jan;19(1S):17-31
10709945
Psychopharmacology (Berl). 2005 Feb;177(4):400-8
15289997